Simcha Therapeutics

Overcoming biological challenges in clinically translatable pathways.

General Information
Company Name
Simcha Therapeutics
Founded Year
2018
Location (Offices)
New Haven, United States +1
Founders / Decision Makers
Number of Employees
15
Industries
Biotechnology, Health and Wellness, Life Sciences +1
Funding Stage
Series B
Social Media

Simcha Therapeutics - Company Profile

Simcha Therapeutics is a clinical-stage biotechnology startup founded in 2018 and headquartered in the United States. The company's slogan "Overcoming biological challenges in clinically translatable pathways" reflects its focus on pioneering first-in-class engineered cytokine therapeutics. Their lead program, ST-067, which is the first decoy-resistant interleukin-18 (IL-18), shows transformational promise as a monotherapy and in combination with other anticancer agents. Currently in a Phase 1/2 clinical trial for patients with solid tumors who have progressed on other immunotherapeutic agents, ST-067 is receiving significant attention.

The company's innovative approach to immune-biology and cytokine engineering has broad potential to support disease-modifying therapeutic options for a range of significant diseases. Moreover, Simcha Therapeutics recently secured a substantial $40.00M Series B investment on 27 January 2022, with notable investors including ArrowMark Partners, BVF Partners, Logos Capital, Rock Springs Capital, Samsara BioCapital, and SR One. This infusion of capital positions Simcha well to advance its promising pipeline and further its mission to address unmet medical needs through groundbreaking immunobiology innovations.

Taxonomy: biopharmaceutical, immunobiology, cytokine therapeutics, engineered cytokines, oncology, clinical-stage, immunotherapy, cancer treatment, precision medicine, biological challenges, immune system modulation, clinical trials, solid tumors, immune-biology, disease-modifying therapy

Funding Rounds & Investors of Simcha Therapeutics (2)

View All
Funding Stage Amount No. Investors Investors Date
Series B $40.00M 6 Biotechnology Value Fund 27 Jan 2022
Series A $25.00M 4 Sequoia Capital China, Pfizer Venture Investments 25 Jun 2020

Latest News of Simcha Therapeutics

View All

No recent news or press coverage available for Simcha Therapeutics.

Similar Companies to Simcha Therapeutics

View All
Intensity Therapeutics, Inc. - Similar company to Simcha Therapeutics
Intensity Therapeutics, Inc. A clinical stage biotechnology company whose mission is to create safer and more efficacious cancer therapies.
SQZ Biotechnologies - Similar company to Simcha Therapeutics
SQZ Biotechnologies Unlocking the full potential of cell therapies for patients around the world
iTeos Therapeutics - Similar company to Simcha Therapeutics
iTeos Therapeutics Cancer Immunotherapies by Design
Mural Oncology - Similar company to Simcha Therapeutics
Mural Oncology Leveraging our protein engineering platform to improve cytokine-based immunotherapies for the treatment of #cancer
Proactive Diagnostics - Similar company to Simcha Therapeutics
Proactive Diagnostics Enabling At-Home Personal Inflammation Monitoring that is Accurate, Fast and Affordable